Services

Build better Models for Reimbursement

Turning Healthcare Data into Reimbursement Advantage

But how can it be used to make it valuable data?

Turning Clinical Impact into Reimbursement Architecture

For Biotech, MedTech, Digital Health, and IVD innovators, success is not determined solely by efficacy.

It is determined by what your technology changes across the patient pathway clinically, operationally, and economically.

Reimbursement bodies do not fund innovation.
They fund demonstrable system improvement.

Getting the most from your data

From Clinical Effect to Economic Consequence

Every innovation creates pathway shifts:

• Shorter length of stay
• Earlier diagnosis
• Reduced complication rates
• Procedure substitution
• Capacity release
• Workforce efficiency
• Downstream cost avoidance

But unless these shifts are quantified within the payment structure, they remain invisible.

At Odelle Technology, we build bespoke mathematical and statistical models that translate pathway impact into reimbursement logic.

When value becomes economically legible, adoption accelerates.

In one national programme, structured value modelling supported a technology moving from 3% to 79% adoption within five years , not through promotion, but through contribution-margin visibility and tariff alignment.

That is pathway engineering.

Our approach is simple

Why Pathway Modelling Is Essential

Biotech reshapes long-term cost curves and survival trajectories.

MedTech alters procedural economics and DRG performance.

Digital health modifies utilisation, adherence, and workforce burden.

IVDs shift diagnostic timing, treatment allocation, and downstream expenditure.

Without pathway-level modelling, these impacts cannot survive HTA scrutiny.

With it, they become fundable.

What We Build

We design jurisdiction-specific economic architectures across the UK and Europe.

Pathway-Level Economic Models

Mapping:

• Episode-of-care costs
• Resource consumption
• Payment flows (DRG, HRG, CCAM, OPS, LPPR)
• Coding alignment
• Reimbursement thresholds
• Regional funding constraints

HTA-Ready Economic Frameworks

Supporting:

• Cost-Utility Analysis (CUA)
• Budget Impact Analysis (BIA)
• Cost-Consequence modelling
• DRG uplift arguments
• LPPR, PECAN, NUB, DiGA submissions
• Tariff negotiation strategy

Contribution-Margin & Hospital-Level Models

Demonstrating to CFOs:

• Revenue impact
• Capacity gains
• Case-mix shifts
• Coding optimisation
• Financial sustainability

This is where adoption decisions are made.

Why Models Must Differ by Country

A model that works in England fails in Germany.

Because incentives differ.

UK:
• ICS budget impact
• NICE thresholds
• HRG contribution margin

Germany:
• DRG rigidity
• OPS coding precision
• NUB pathways
• Medizincontroller economics

France:
• LPPR listing
• CCAM coding
• CNEDiMTS grading
• ARS oversight

Spain & Italy:
• Regional HTA fragmentation
• Procurement consortia
• Decentralised budgets

The mathematics must reflect the incentive structure.

We do not deploy templates.
We build country-specific reimbursement logic.

From Data to Adoption Strategy

Our models allow innovators to answer:

Where does pathway value emerge?
How does it translate into reimbursement?
Which regions generate positive economic signal first?
What real-world evidence must be generated to satisfy HTA?
How does this move from pilot to national scale?

This is not retrospective analytics.

It is a forward reimbursement architecture.

Our Approach

We:

Map your technology across the full patient pathway
Integrate clinical, operational, and economic data
Embed reimbursement structure
Stress-test funding scenarios
Deliver transparent, interactive modelling tools

Built deliberately in Excel and Visual Basic:

• Transparent
• Audit-ready
• Rapidly adaptable
• No vendor lock-in
• Immediately usable by CFOs and pricing teams

No black boxes.
No generic dashboards.
Only mathematically legible value.

The Outcome

For Biotech, MedTech, Digital, and IVD innovators, pathway modelling enables:

• Clear HTA positioning
• Robust Budget Impact justification
• Tariff alignment
• Regional rollout prioritisation
• Investor-grade economic validation
• Scalable reimbursement architecture

This is modern market access:

Engineering adoption through economic clarity..

To find out more and discuss your project, please contact us.

Testimonials

With over 65 years combined experience, we have a long track record of delivering timely solutions for our clients.

Odelle Technology’s voluntary support was pivotal in securing two NICE guidelines and establishing new HRG codes for Deep Brain Stimulation (DBS) within the NHS. They didn’t just navigate the complexities of regulatory and economic frameworks—they energised my team of scientists, bringing their expertise to life and amplifying the impact of our work. Their ability to connect our efforts with commissioners and NHSE made DBS more accessible to patients across the UK and further. Their dedication and collaborative spirit were transformative, and I would wholeheartedly recommend them as a team of experts in getting things done in advancing healthcare innovation.

Professor of Neurosurgery

Founder of Oxford Functional Neurosurgery
Consultant Neurosurgeon
Oxford University Hospitals NHS Foundation Trust

We chose to work with Steven on KOL interviews and payer perspectives after speaking to a few firms. Steven is extremely friendly, kind and a great communicator. In addition to these, he understood our situation as a start up and tailored a custom solution for us. Steven's passion makes him a natural when you need someone to speak to people and gain insights for your product. I would recommend Steven and look forward to continue our work together.

Anand Nandakumar Ph.D

CEO, Founder
TherageniX

Steven has done an amazing job to help support EyeYon's commercial efforts in Europe, which has allowed better access to EyeYon's products in major EU markets.

Charles Holmes

Chief Commercial Officer
EyeYon Medical

It’s been a great experience working alongside the team at Odelle, particularly when it comes to emerging trends. The expertise and insight that the team have, coupled with their adaptability has helped us to move the needle quickly on our market access strategy, in line with market demands.

Chris Gray

European Market Access Manager
CMR Surgical

Steven has amazing medical device contacts throughout the UK, Europe and into the US. He has an excellent understanding of the complex way in which the medical device system works. He also understands the re-imbursement processes in the UK and Europe. He is intelligent, hard working, honest and deeply invested in medical device technology and the connections which bring these technologies to market. He is a genuine facilitator and cares about outcomes and results.

Professor Rob Philips

Executive Chairman, Chief Executive Officer and Chief Scientist
USCOM

Odelle developed a value analysis tool for our new and disruptive technology in the breast cancer pathway, which allows us to work hand in hand with our customers to accurately reflect individual hospital practice in country specific healthcare systems. Odelle showed a real desire to understand our business and our objectives; they delivered to our brief, on time, on budget and coupled this with first class communication.

Amanda Durman

Vice President
Merit Oncology, EMEA
Merit Medical Systems Inc.

Odelle were invaluable in securing several procedural clinical HRG codes for interventional cardiology in the United Kingdom. These have facilitated the greatest adoption of three lifesaving technologies that have enabled many thousand of live to be saved. Their intelligence and superb planning was something we in the British Cardiovascular Society are immensely grateful for.

Professor Anthony Gershlick

University of Leicester and University Hospitals of Leicester NHS Trust

Excellent insights and deep understanding of the project we worked on. Spent time to really understand our needs which resulted in a great set of strategic suggestions to the company. Highly recommend.

Steve Bell

Chief Commercial Officer
CMR Surgical

I have personally worked with Steven for a number of years. Steven’s insight, breadth of knowledge, intelligence and passionate sense of purpose are a huge asset to any project. In particular innovation adoption, tech incubation, regulatory frameworks globally and reimbursement thinking. And, he is a good man!

Simon Tarry

Managing Director
Smith & Nephew UKI Nordics

I have worked with Steven many times for numerous clients in various verticals and always find his energy and work ethic endless, his network unmatched, and his sense of humor priceless. If you are looking to launch an innovative MedTech product and/or service into EMEA look no further Steven will get you connected, validated, partnered and capturing market share faster than anyone I know!

Stephen Wilson

Sr. Director, Global Strategic Innovation
Hologic, Inc.

Steven is an extremely able individual that really understands the healthcare and technology sector better than anyone else who I have ever come across. He makes it a priority of his to not only understand his clients but also his customers and as such its a pleasure doing business with him. Whether its market access, new technologies, generating opportunities out of thin air and merely taking time to think about the future then Steven is a star. Not only that but he makes time for YOU which shows how unselfish he is and how he invests his time in others. Make the time to get to know Steven and you will never regret it!

Martin Wakeley

Chairman of Clinical Commissioning Group
NHS, United Kingdom

Steven has assisted me with European business development and product introduction on multiple occasions since 2014. He is an amazing networker resulting in him being the most well connected person I know. He opens doors in health systems, partners, and distributors resulting in win-win collaborations, and always does it in a pleasant and fun way. Great to work with. If you are looking at taking a product through clinical validation and launching in the EMEA market, Steven is the one person you have to talk to.

Stewart Barlett

CEO
Ferronova

Our clients

Since our establishment, we have worked with a number of industry-leading clients, working to provide an efficient, successful service that delivers the best possible results for you. Some of these clients include:

+44 (0) 7804 623 339

Unit 1-2
Field View Business Park
Bicester
UNITED KINGDOM
OX27 7SG

15 Rue de President Roosevelt
Pons
FRANCE
17800